These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 29482402)
1. Etanercept for the treatment of rheumatoid arthritis. Zhao S; Mysler E; Moots RJ Immunotherapy; 2018 Mar; 10(6):433-445. PubMed ID: 29482402 [TBL] [Abstract][Full Text] [Related]
2. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis. Chadwick L; Zhao S; Mysler E; Moots RJ Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183 [TBL] [Abstract][Full Text] [Related]
3. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)). Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856 [TBL] [Abstract][Full Text] [Related]
4. GP2015: An Etanercept Biosimilar. Deeks ED BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131 [TBL] [Abstract][Full Text] [Related]
6. GP2015 as a promising therapy for rheumatoid arthritis. Fitton J; Giollo A; Buch MH Expert Opin Biol Ther; 2018 Apr; 18(4):477-481. PubMed ID: 29558865 [TBL] [Abstract][Full Text] [Related]
7. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316 [TBL] [Abstract][Full Text] [Related]
8. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Emery P; Vencovský J; Sylwestrzak A; Leszczyński P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J Ann Rheum Dis; 2017 Jan; 76(1):51-57. PubMed ID: 26150601 [TBL] [Abstract][Full Text] [Related]
9. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892 [No Abstract] [Full Text] [Related]
10. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793 [TBL] [Abstract][Full Text] [Related]
11. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK. Tarallo M; Onishchenko K; Alexopoulos ST J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527 [No Abstract] [Full Text] [Related]
13. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Scherlinger M; Langlois E; Germain V; Schaeverbeke T Semin Arthritis Rheum; 2019 Apr; 48(5):927-932. PubMed ID: 30093238 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362 [TBL] [Abstract][Full Text] [Related]
15. Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases. Burness CB; Duggan ST BioDrugs; 2016 Aug; 30(4):371-8. PubMed ID: 27455991 [TBL] [Abstract][Full Text] [Related]
16. LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. Song YW; Park YB; Kim J Expert Opin Biol Ther; 2021 Jan; 21(1):1-8. PubMed ID: 31801395 [No Abstract] [Full Text] [Related]
17. Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance. Colina M; Khodeir M; Rimondini R; Valentini M; Campomori F; Corvaglia S; Campana G Clin Drug Investig; 2024 Mar; 44(3):141-148. PubMed ID: 38294672 [TBL] [Abstract][Full Text] [Related]
19. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Bae SC; Kim J; Choe JY; Park W; Lee SH; Park YB; Shim SC; Lee SS; Sung YK; Choi CB; Lee SR; Park H; Ahn Y; Ann Rheum Dis; 2017 Jan; 76(1):65-71. PubMed ID: 26905864 [TBL] [Abstract][Full Text] [Related]
20. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]